BiotechTube

EDP 305 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Presumptive NAFLD

Conditions

Presumptive NAFLD

Trial Timeline

Sep 1, 2016 → Jun 1, 2017

NCT ID
NCT02918929

About EDP 305 + Placebo

EDP 305 + Placebo is a phase 1 stage product being developed by Enanta Pharmaceuticals for Presumptive NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT02918929. Target conditions include Presumptive NAFLD.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02918929Phase 1Completed

Other Products from Enanta Pharmaceuticals

EDP-305 Dose 1 + EDP-305 Dose 2 + PlaceboPhase 2
44
EDP-938 + PlaceboPhase 2
44
EDP-305 1.5 mg + EDP-305 2 mg + PlaceboPhase 2
44
EDP-938 + PlaceboPhase 2
44
EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + PlaceboPhase 2
44